Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435

Benzinga · 1d ago
Wells Fargo analyst Yanan Zhu maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $400 to $435.